The Impacts of Multivitamin and Mineral Supplementation on Cellular Metabolism and Healthy Aging

As the global population of older adults continues to expand, it is imperative to identify accessible and evidence-based interventions to support healthy aging. Among the key biological hallmarks of aging, mitochondrial dysfunction is highly modifiable and especially responsive to lifestyle interventions such as diet and exercise. Importantly, our clinical studies demonstrate that mitochondrial bioenergetics plays a key role in the physical and cognitive abilities of older adults. Thus, identifying interventions that can improve mitochondrial bioenergetics is a promising avenue for the development of healthy aging interventions.

Multivitamin and mineral (MVM) dietary supplements have been used to support general health and nutritional status for years, particularly in older adults who are more susceptible to nutritional deficiencies due to factors such as reduced appetite, malabsorption, and polypharmacy. Observational studies consistently demonstrated that older adults exhibit higher rates of nutritional deficiencies, and that MVM supplementation may ameliorate these burdens. More recently, evidence suggests that MVM use may also confer functional health benefits; for example, the COSMOS-Mind trial demonstrated efficacy of MVM on global cognition, memory, and executive function in 2262 participants. Notably, most MVM studies are longitudinal and occur over the course of many years. A significant gap remains in understanding the acute effects of MVM supplementation on health and aging. Can rapid, measurable improvements in health be observed with MVM use? Moreover, what are the cellular mechanisms that can underlie the benefits of MVM use?

Description of Study Intervention: The study cohort will consist of 150 sedentary men and women aged 40-60-years of age. A double-blind, three-arm, placebo-controlled randomized clinical trial will be conducted. Participants will receive a daily oral tablet containing one of two possible formulations of vitamins and minerals or a placebo. The three groups will be MVM "GOLD" blend formula, the US Restage MVM "US CORE", and the placebo group. Specific formulations of the three tablets are detailed in the 2025 Stability Provisional Expiry for Centrum Gold Blend Tablets (FN-2492-0001), Centrum US Restage Blend Tablets (FN-2493-0001, and Placebo of Centrum Gold Blend Tablets (FN-0436-0231) -

Assessments:

The baseline study visit will occur at least 2 weeks after, but no more than 4 weeks after, the initial screening visit (actigraph will be deployed at screening and will be worn for 2 weeks).